Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This compound is a synthetic small molecule with the chemical formula C21H18N6O4S₂ and a molecular weight of approximately 482.5 g/mol[1][5]. It is also known as "CHEMBL1206212" and "2PTUM-IPAA"[7]. The structure features a thiazole, imidazole, phenoxy, and acetic acid moiety connected via urea and thioether linkages. It is classified as an experimental drug with no approved indications or clinical trial activity reported to date[1][3][6]. Its mechanism of action has not been characterized in public databases such as DrugBank or PubChem; it may have been synthesized for research purposes related to amide derivatives or enzyme inhibition but lacks published pharmacological data[6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 2-(4-(2-((3-(5-(pyridin-2-ylthio)thiazol-2-yl)ureido)methyl)-1H-imidazol-4-yl)phenoxy)acetic acid.